NIH infectious disease institute leader steps down amid outbreak concerns

The acting director of NIH’s premier infectious-disease institute stepped down just as lawmakers were pressing the agency on how it would handle threats such as Ebola and hantavirus, deepening concerns about whether the government’s outbreak-response machinery is stable enough for the next emergency.

Sen. Tammy Baldwin told the Senate hearing on May 21 that Jeffery K. Taubenberger had left his post and would not testify as scheduled. Sen. Patty Murray also referred to his departure. Jay Bhattacharya, who became NIH director on April 1 after Senate confirmation on March 25, did not dispute that Taubenberger had gone. Instead, he said the institute needed new leadership because it would no longer focus on civilian biodefense.

That exchange mattered because the National Institute of Allergy and Infectious Diseases sits at the center of federal research on infections, vaccines and outbreak preparedness. NIAID says Taubenberger had overseen a $6.6 billion budget since being named acting director in April 2025, and the institute is one of NIH’s 27 institutes and centers. Its mission is to conduct and support research to understand, treat and prevent infectious and allergic diseases.

The leadership shift also landed as NIAID and NIH leaders were laying out a new strategic vision in January 2026 that emphasized the most impactful infectious diseases facing Americans, along with fundamental immunology and research on allergic and autoimmune disease. That framing points to a broader reordering of priorities inside one of the federal government’s most consequential biomedical institutions.

The stakes are high because NIAID has long been central to crisis response. Anthony S. Fauci led the institute from 1984 to 2022 and oversaw work on emerging threats including Ebola, Zika and COVID-19. NIH and NIAID materials say the institute played a major role in Ebola research during the 2014-2016 West African epidemic, including Phase 1 and Phase 2 testing of the rVSV-ZEBOV vaccine. The outbreak, which spread through Guinea, Liberia and Sierra Leone, became the largest on record, with more than 28,646 reported cases and more than 11,000 deaths.

Baldwin warned that the upheaval amounted to a leadership vacuum at a time when the country is still confronting multiple infectious-disease pressures. The Department of Health and Human Services, which oversees NIH, did not answer questions about Taubenberger’s exit or the institute’s role in Ebola response efforts. For an institute with a $6.6 billion budget and a central role in pandemic preparedness, the loss of an acting director was more than a personnel change. It was a test of whether federal health leadership can stay aligned with outbreak risk.